From Yahoo Finance: 2025-06-18 08:27:00

India and the US are close to finalizing a trade agreement to boost annual bilateral trade to $500 billion by 2030. The pharmaceutical sector plays a crucial role, with the US being India’s largest export market for pharmaceuticals. India has proposed tariff exemptions and IP reforms to secure favorable terms in the deal.

President Trump’s threat of sector-specific tariffs on pharmaceuticals has prompted India to propose measures like technology transfer access and patent law reforms. India aims to provide generic medicines at significantly lower prices to the US market post-patent expiry. The US is concerned about India’s intellectual property rights but may consider certain concessions.

India seeks greater access to advanced technologies in the pharmaceutical sector to enhance innovation. The US is cautious due to concerns over intellectual property rights. India also proposes to increase US manufacturing by Indian pharma companies to navigate potential import duties. The proposal aligns with Trump’s push for domestic pharmaceutical production.

The future of India-US pharmaceutical trade hinges on the ongoing negotiations and the proposed measures to address tariff threats and enhance collaboration in technology and manufacturing. The goal is to secure a mutually beneficial trade agreement that supports both countries’ interests in the pharmaceutical sector.



Read more at Yahoo Finance: the future of India-US pharmaceutical trade